Eli Lilly Co Drug Patent Portfolio

Eli Lilly Co's Family Patents

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Will Immunology Medications Keep Boosting AbbVie's Revenue in 2026? - TradingView

20 Feb, 2026

Eli Lilly shares decline despite positive psoriasis results for Zepbound and Taltz; investors are looking ahead to the company's next moves.

19 Feb, 2026

Disregard Ozempic: This Leading Obesity Medication Company Is Securing the Largest Share of the GLP-1 Market Boom.

19 Feb, 2026

Eli Lilly Enters Competition for Promising Inflammation Treatment, Acquiring CSL Drug Rights for $100 Million

18 Feb, 2026